Lesson
Build the Neuromuscular Junction Failure
Myasthenia gravis is an autoimmune disorder of postsynaptic neuromuscular transmission. The motor nerve can release acetylcholine normally, yet the end plate cannot translate every impulse into dependable muscle contraction.
- Acetylcholine
- AChR
- MuSK
- LRP4
- Safety factor
The motor nerve releases acetylcholine; autoimmune MG primarily disrupts its postsynaptic effect.
AChR, MuSK, and LRP4 biology determines whether the end plate can translate the signal.
Postsynaptic injury lowers reserve, so contraction fails as activity continues and improves with rest.
Begin at the motor end plate
Acetylcholine crosses the synaptic cleft and activates nicotinic receptors on skeletal muscle. Acetylcholinesterase rapidly terminates the signal so repeated contraction depends on intact release, receptor density, end plate architecture, and recovery.
Separate antibody phenotypes
Most patients have antibodies to the acetylcholine receptor. MuSK antibodies disrupt receptor clustering and junction organization, while LRP4 and other antibodies explain a smaller share. Seronegative disease remains possible when standard assays are negative.
Understand fatigability
Transmission begins with a reduced safety factor. Repeated activation exposes the deficit, producing weakness that worsens with sustained use and often improves with rest.
Keep sensation and cognition distinct
The disorder affects voluntary skeletal muscle rather than sensory nerves, smooth muscle, or thought. Sensory loss, bowel paralysis, or confusion should reopen the differential diagnosis.
Use chemistry where it changes care
Pyridostigmine is a reversible carbamate acetylcholinesterase inhibitor. Its permanently charged quaternary ammonium group limits central nervous system penetration and concentrates its clinical effect at peripheral cholinergic synapses.
Quick check
Checking for saved practice…
Lesson
Recognize the Pattern and Protect Breathing
The diagnostic pattern is fluctuating, fatigable weakness, but the first clinical responsibility is to identify bulbar or respiratory compromise that can progress faster than routine outpatient evaluation.
- Ptosis and diplopia
- Bulbar weakness
- Neck flexion
- FVC and NIF
- Impending crisis
Ocular, bulbar, axial, limb, and respiratory weakness fluctuate with use and time.
Wet voice, secretion pooling, choking, and weak cough can precede airway loss.
FVC, NIF, speech, gas exchange, and trajectory matter even when oxygen saturation is normal.
Recognize common presentations
Ptosis, diplopia, facial weakness, nasal speech, chewing fatigue, dysphagia, neck weakness, proximal limb weakness, and shortness of breath can fluctuate over hours and worsen later in the day or with illness.
Do not use age to exclude MG
MG can begin at any age. Younger-onset disease is more common in women, while older-onset disease is common in men. A textbook average age does not define eligibility for diagnostic testing; the pattern of fatigable weakness matters more than matching a demographic profile.
Find bulbar risk
Weak cough, pooling secretions, wet voice, choking, prolonged meals, nasal regurgitation, and inability to handle saliva signal aspiration and airway risk even before severe limb weakness appears.
Assess ventilation directly
Pulse oximetry can remain normal until late because oxygenation is not the same as ventilatory muscle strength. Serial forced vital capacity, negative inspiratory force, bedside speech and cough, gas exchange, and trajectory guide escalation.
Define crisis operationally
Impending crisis means rapid clinical worsening that may lead to intubation. Manifest crisis includes worsening MG that requires intubation or noninvasive ventilation to prevent intubation; routine postoperative ventilatory support alone does not meet this definition. The response is monitored respiratory care, not a delayed office medication adjustment.
Protect the differential
Lambert Eaton syndrome, botulism, brainstem disease, motor neuron disease, myopathy, thyroid eye disease, medication toxicity, and functional disorders can overlap. Reflexes, autonomic symptoms, pupils, sensory findings, central signs, and response to activity help separate them.
Quick check
Checking for saved practice…
Lesson
Confirm the Phenotype and Search for Thymic Disease
Diagnosis integrates the clinical pattern with antibody testing and neuromuscular physiology. The workup also identifies thymoma and competing conditions because those findings change treatment.
- AChR antibodies
- MuSK antibodies
- Repetitive stimulation
- Single fiber EMG
- Chest imaging
AChR is usually first, followed by MuSK and selected additional testing when suspicion remains.
Repetitive stimulation and single fiber EMG can reveal junction failure.
Chest CT or MRI identifies thymoma and thymic abnormality that change management.
Start with phenotype and antibodies
AChR binding antibodies are the usual first serologic test. If negative and suspicion remains, assess MuSK and selected additional antibodies according to specialist pathways. A positive antibody supports autoimmune MG in the correct clinical context.
Resolve negative or discordant results
Persistent suspicion after standard serology warrants specialist review, cell-based antibody assays and neurophysiology. Reconsider congenital syndromes, myopathy and structural causes. Negative serology plus negative neurophysiology in persistent ptosis or diplopia warrants brain and orbital imaging as appropriate. Include thyroid-function testing.
Use electrodiagnostic physiology
Repetitive nerve stimulation can demonstrate a decremental response. Single fiber electromyography is highly sensitive for impaired neuromuscular transmission but is not specific enough to replace clinical interpretation.
Use bedside tools narrowly
An ice pack can transiently improve ptosis and support the diagnosis in an ocular presentation. Bedside response does not classify antibody phenotype or exclude central and structural causes.
Image the thymus
ABN 2025 recommends chest CT or MRI for suspected MG, including ocular or seronegative presentations. A chest radiograph alone is insufficient to exclude thymoma. A tumor requires surgical evaluation even when weakness is controlled.
Build a baseline
Document MG activities of daily living, examination distribution, respiratory and bulbar status, thyroid and autoimmune context, medicine exposures, infection, reproductive plans, and the functional outcomes that treatment should improve.
Quick check
Checking for saved practice…
Lesson
Use Pyridostigmine Around Function
Pyridostigmine increases acetylcholine exposure at the neuromuscular junction and can improve strength quickly. It is symptomatic therapy, not a treatment for the pathogenic antibody response.
- Reversible AChE inhibition
- Timing around meals
- Renal elimination
- Muscarinic toxicity
- Cholinergic weakness
Short duration makes dose timing as important as total exposure.
Renal function, response, and muscarinic symptoms define the useful dose.
Diarrhea, sweating, fasciculation, and paradoxical weakness make blind escalation unsafe.
Target the working day
Immediate release doses are often timed before meals or demanding activities because onset and duration are limited. Extended release can support selected overnight or morning goals but has less predictable absorption and does not replace individualized daytime dosing.
Identify the oral formulation
Mestinon immediate-release tablets contain 60 mg; the solution contains 60 mg per 5 mL. Timespan contains 180 mg with prolonged release and is not equivalent to taking 180 mg immediate release at once. Verify the formulation, concentration and prescribed schedule before dispensing or converting a dose.
Separate indications and routes
The current Regonol injection label is IV-only for reversal of nondepolarizing neuromuscular blockade. Do not infer an IM route or routine crisis treatment from a general pyridostigmine drug entry. Soman-related pyridostigmine use is pretreatment under a separate product protocol, not treatment after poisoning.
Reassess use during crisis
Airway and ventilatory support take priority. In an intubated myasthenic crisis, neurology generally withholds pyridostigmine because increased secretions can worsen aspiration and ventilation problems. An injection is not a routine substitute for oral doses in this setting.
Titrate clinically
ABN 2025 starts adults at 30 mg three or four times daily, with gradual titration to the lowest effective dose. Its protocol permits divided doses up to 360 mg/day but notes little additional benefit above that level. Requirements above 300 mg/day should prompt specialist review and consideration of additional disease-directed treatment. The older label and RxPrep describe substantially higher totals; those are not routine starting doses or goals.
Respect renal elimination
Pyridostigmine is substantially eliminated unchanged by the kidney. Reduced kidney function can increase exposure, so lower requirements and careful titration may be appropriate.
Recognize muscarinic toxicity
Diarrhea, abdominal cramping, nausea, salivation, sweating, miosis, urinary urgency, and bronchial secretions indicate excess peripheral cholinergic effect. Glycopyrrolate is sometimes used under specialist direction for troublesome muscarinic symptoms. Suppressing those signs does not correct nicotinic weakness and may hide excessive pyridostigmine exposure; keep reassessing dose and respiratory function.
Review glaucoma medicines by mechanism
Glaucoma itself is not listed as a blanket Mestinon contraindication. Reconcile the actual eye drops: beta blockers can add bradycardia or neuromuscular concern, and other cholinesterase inhibitors can add cholinergic effects. Coordinate with ophthalmology rather than stopping vision-preserving treatment or assuming all glaucoma therapies behave alike.
Recognize nicotinic excess
Fasciculations, muscle cramps, and paradoxical weakness can occur with excess acetylcholinesterase inhibition. Mechanical intestinal or urinary obstruction is a contraindication, and asthma, dysrhythmia, secretion burden, and bradycardia require caution.
Quick check
Checking for saved practice…
Lesson
Control Autoimmunity With a Time Horizon
Corticosteroids and steroid sparing immunotherapies reduce autoimmune activity, but their onset and toxicity differ. The plan must bridge current function while protecting long term health.
- Prednisone
- Early worsening
- Azathioprine
- Mycophenolate
- Monitoring
Pyridostigmine and rescue therapy may cover the delay before immune control appears.
Corticosteroids act sooner but can worsen weakness early; steroid sparing drugs can take months.
Function, crisis, infection, organ toxicity, bone, metabolic, and reproductive risks define success.
Use corticosteroids deliberately
Prednisone is effective but may transiently worsen weakness during the first days or weeks, especially with high initial exposure or substantial bulbar disease. High risk initiation may require slower escalation or monitored care.
Distinguish outpatient steroid titration
ABN 2025 uses prednisolone 5-10 mg daily initially, increasing by 5 mg every three to five days toward response, with initial targets of 20 mg/day for ocular or 30 mg/day for generalized disease. Higher requirements need specialist review. This outpatient protocol is not a crisis regimen or an instruction for patients to self-adjust.
Taper according to sustained control
After remission, steroid reduction is gradual and individualized. Monitor for recurrent MG and adrenal suppression; do not stop prolonged therapy abruptly. Fatigue alone does not establish worsening autoimmune weakness or justify dose escalation.
Select a steroid sparing strategy
Azathioprine, mycophenolate, tacrolimus, cyclosporine, and other immunotherapies have distinct onset, laboratory, interaction, organ toxicity, pregnancy, malignancy, and infection considerations. Choice is patient specific and specialist managed.
Plan azathioprine safety
Check TPMT before treatment under the MG guideline; deficient TPMT or NUDT15 function increases marrow toxicity and may require an alternative or reduced dose. Testing never replaces blood counts. The US Imuran label specifies CBC and platelets weekly in month one, twice monthly in months two and three, then monthly or more often with treatment changes. Also monitor liver function and counsel about infection, bruising and sun protection.
Intercept xanthine oxidase interactions
Allopurinol inhibits azathioprine inactivation. If combined deliberately, the Imuran label calls for approximately one-third to one-quarter of the usual azathioprine dose with close monitoring; resolve the prescription with the treating team. Concomitant febuxostat is not recommended. Do not dispense an unchanged azathioprine regimen with a new xanthine oxidase inhibitor without review.
Include phenotype-directed rituximab
ABN 2025 recommends early specialist consideration of rituximab for MuSK MG with bulbar symptoms. It also supports consideration in early moderate-to-severe generalized AChR disease, while long-term retreatment evidence is less certain. MG use is off-label in the US; do not substitute an oncology regimen or assume one schedule fits every phenotype.
Screen before B-cell depletion
Before rituximab, obtain CBC and hepatitis B testing including HBsAg and anti-HBc. A negative surface antigen alone does not exclude reactivation risk. Prior or current HBV requires specialist prevention and monitoring planning. Review vaccines, infections and immunoglobulins; provide infusion-reaction precautions and teach prompt assessment of new neurologic symptoms because PML is a serious labeled risk.
Protect reproductive safety with mycophenolate
Mycophenolate can cause pregnancy loss and congenital malformations. Plan a safer MG regimen before conception with the specialist team. CellCept labeling calls for pregnancy testing immediately before treatment, again eight to ten days later, and during follow-up. Females of reproductive potential need acceptable contraception during treatment and for six weeks afterward; oral contraceptive users need an additional barrier method. Sexually active male patients and/or their partners should use effective contraception during treatment and for at least 90 days afterward.
Monitor mycophenolate toxicity
CBC surveillance detects marrow suppression; report infection, unexpected bleeding or bruising promptly. Diarrhea and other gastrointestinal effects can limit treatment, and severe symptoms require evaluation. The CellCept label suggests CBC checks weekly in month one, twice monthly in months two and three, then monthly through year one. MG dosing and response assessment follow a specialist protocol rather than transplant targets.
Track tacrolimus exposure and organ effects
Tacrolimus can cause kidney injury, hyperkalemia, hypertension, hyperglycemia and neurotoxicity. Follow trough concentrations alongside renal function, electrolytes, blood pressure and glucose. CYP3A inhibitors can sharply raise exposure, while inducers can lower it; adding or stopping interacting medicines requires prompt dose and monitoring review. Immediate-release and extended-release products are not automatically interchangeable.
Keep cyclosporine formulations distinct
Modified cyclosporine, such as Neoral, and nonmodified Sandimmune are not bioequivalent. Any conversion needs prescriber supervision and additional monitoring. Cyclosporine can cause hypertension, kidney and liver injury, hyperkalemia, tremor and gingival overgrowth. Review blood pressure, renal function, electrolytes, liver tests and drug exposure; check interactions and avoid grapefruit. MG treatment uses specialist dosing rather than an automatically imported transplant regimen.
Respect delayed benefit
Azathioprine and several alternatives can take months to show meaningful effect. Do not declare failure prematurely or expose the patient to indefinite corticosteroid toxicity without a documented reassessment point.
Build surveillance before treatment
Baseline blood counts, liver and kidney function, infection and vaccination review, reproductive planning, drug interactions, bone and metabolic risk, and product specific testing should be completed before or early in therapy.
Measure both disease and harm
Follow function, bulbar and respiratory symptoms, examination, exacerbations, rescue use, corticosteroid exposure, infection, blood pressure, glucose, bone health, weight, mood, eyes, laboratory toxicity, and patient priorities.
Quick check
Checking for saved practice…
Lesson
Match Thymectomy to the Disease
Thymectomy is mandatory to evaluate when thymoma is present and can improve long term outcomes in selected nonthymomatous AChR positive generalized disease. It is not a universal procedure for every antibody phenotype.
- Thymoma
- AChR positive generalized MG
- Age 18 to 50
- Elective stability
- MuSK limitation
A thymic tumor requires surgical evaluation while MG is stabilized.
Younger adults with generalized AChR positive nonthymomatous disease have the clearest benefit.
Elective surgery is safer after respiratory and bulbar function are controlled.
Treat thymoma as its own indication
A thymic tumor requires thoracic surgical and oncology evaluation. Complete resection is pursued when feasible, while MG is stabilized and managed before, during, and after surgery.
Use consensus criteria
Current international guidance supports discussing thymectomy early in nonthymomatous generalized AChR antibody positive MG, particularly from ages 18 through 50, to improve outcomes and reduce immunotherapy burden.
Avoid a rigid age cutoff
The 2020 international consensus emphasizes ages 18-50. ABN 2025 also supports considering nonthymomatous AChR-positive generalized disease at ages 50-65, acknowledging more limited evidence. Age alone should not end the discussion; assess comorbidity, disease duration, treatment burden, surgical fitness and patient goals with the specialist team.
Consider inadequate control
Thymectomy should be strongly considered when a patient with generalized AChR positive disease has an inadequate response to initial immunotherapy or intolerable adverse effects from that therapy.
Operate electively when stable
The procedure should occur when the patient is clinically stable because perioperative bulbar or respiratory weakness increases risk. Preoperative rescue therapy may be used selectively in high risk patients.
Respect phenotype limits
Current evidence does not support thymectomy as routine immune treatment for MuSK, LRP4, or agrin antibody disease. Ocular disease requires individualized specialist discussion rather than automatic extrapolation.
Quick check
Checking for saved practice…
Lesson
Treat Myasthenic Crisis as Respiratory Failure
Rapid immunomodulation is only one part of crisis care. Airway protection, ventilatory support, trigger treatment, secretion management, nutrition, thrombosis prevention, and careful medication review determine survival and recovery.
- FVC and NIF
- Intubation
- Plasma exchange
- IV immune globulin
- Precipitating factor
Cough, secretions, FVC, NIF, speech, and trajectory guide airway timing.
Select rapid therapy from phenotype, access, hemodynamics, kidney function, thrombosis risk, and speed.
Infection, aspiration, surgery, treatment interruption, and medication exposure must be corrected.
Do not wait for arterial hypoxemia
Serial respiratory mechanics, weak cough, secretion burden, bulbar function, gas exchange, work of breathing, speech, and clinical trajectory should drive ICU and airway decisions. Elective intubation is safer than a crash airway.
Choose rapid immune rescue
Plasma exchange and IV immune globulin are accepted short term treatments for crisis and severe exacerbation. Plasma exchange often acts faster and is particularly useful in MuSK disease, while vascular access, hemodynamics, kidney function, thrombosis risk, infection, and availability shape selection.
Verify the IVIG course before infusion
ABN 2025 describes crisis IVIG as a total 2 g/kg course using ideal body weight, usually divided over five days. Confirm the institution’s dosing-weight policy, product, infusion rate and renal/thrombotic precautions. The course total is not a daily dose. For a prescribed dosing weight of 60 kg, 120 g total divided equally over five days is 24 g daily.
Treat the trigger
Respiratory infection, aspiration, surgery, pregnancy related change, medication exposure, treatment interruption, and uncontrolled disease are common contributors. Culture and antimicrobial choices must account for MG medication cautions.
Handle pyridostigmine thoughtfully
During intubated crisis, acetylcholinesterase inhibition is often reduced or held because secretions complicate airway care. It is restarted and titrated as strength and extubation readiness improve under specialist direction.
Plan extubation beyond one number
Respiratory mechanics, cough, secretion clearance, bulbar strength, gas exchange, fatigue over time, and trigger control must align. A single improved measurement does not guarantee durable airway protection.
Quick check
Checking for saved practice…
Lesson
Lower Pathogenic IgG Through FcRn
FcRn blockers interrupt IgG recycling, accelerating reduction of circulating IgG, including pathogenic autoantibodies. Products differ in antibody requirements, route, schedule, age, and product specific safety.
- Efgartigimod
- Rozanolixizumab
- Nipocalimab
- IgG reduction
- Vaccination and infection
Less FcRn rescue sends more IgG toward degradation.
Efgartigimod, rozanolixizumab, and nipocalimab differ by phenotype, age, route, and schedule.
Review active infection, live vaccines, treatment cycles, and Fc containing therapies.
Understand the target
The neonatal Fc receptor rescues IgG from lysosomal degradation. Blocking FcRn lowers circulating IgG without directly depleting B cells, so effect and infection risk must be monitored across treatment cycles.
Place efgartigimod accurately
Efgartigimod alfa is available as intravenous Vyvgart and subcutaneous Vyvgart Hytrulo. FDA expanded the adult generalized MG indication in May 2026 beyond the older AChR positive restriction. Current labeling should be checked before every prescribing decision.
Dose intravenous efgartigimod
Vyvgart is infused over one hour once weekly for four weeks: 10 mg/kg per dose, capped at 1,200 mg for patients weighing at least 120 kg. Dilute to a final volume of 125 mL with 0.9% sodium chloride. Later cycles depend on clinical assessment, not an automatic continuous weekly schedule.
Distinguish Hytrulo presentations
For gMG, both subcutaneous presentations use four weekly doses per cycle. The prefilled syringe supplies 1,000 mg efgartigimod with 10,000 units hyaluronidase over 20-30 seconds; the vial supplies 1,008 mg with 11,200 units over 30-90 seconds. Trained patients or caregivers may administer the syringe; the vial requires a healthcare professional. Do not dilute Hytrulo or give it intravenously.
Keep indication-specific schedules separate
Hytrulo treatment for CIDP uses ongoing weekly dosing, whereas gMG uses clinically reassessed cycles. Verify indication and presentation before scheduling or dispensing. Monitor for hypersensitivity for at least 30 minutes after Hytrulo administration and provide a plan for urgent symptoms.
Place rozanolixizumab accurately
Rystiggo is approved for adults with AChR or MuSK antibody positive generalized MG. It is administered by a healthcare provider as a weight based subcutaneous infusion once weekly for six weeks, with later cycles based on clinical evaluation.
Apply Rystiggo weight bands
The US dose is 420 mg below 50 kg, 560 mg from 50 to below 100 kg, and 840 mg at 100 kg or above. A healthcare professional administers the subcutaneous pump infusion at up to 20 mL/hour weekly for six weeks. Safety of another cycle starting before day 63 from the previous cycle start is not established. Observe during infusion and for 15 minutes afterward; do not flush the line after completion.
Place nipocalimab accurately
Imaavy is approved for AChR or MuSK antibody positive generalized MG from age 12. It uses a 30 mg/kg intravenous loading dose, then 15 mg/kg two weeks later and every two weeks, with observation for infusion and hypersensitivity reactions.
Prepare and observe Imaavy correctly
Infuse the initial gMG dose over at least 30 minutes and maintenance doses over at least 15 minutes. Dilute with 0.9% sodium chloride to 250 mL when weight is at least 40 kg, or 100 mL for eligible patients below 40 kg. Observe for 30 minutes after every infusion. The separate warm autoimmune hemolytic anemia schedule must not be substituted for the gMG regimen.
Build shared class safety
Delay treatment during active infection when the label directs, review age appropriate vaccines before treatment, avoid live vaccines during IgG lowering treatment, and monitor for reduced effectiveness of immunoglobulin products or Fc containing monoclonal therapies. Rystiggo also carries an aseptic meningitis warning.
Quick check
Checking for saved practice…
Lesson
Block Terminal Complement Without Underestimating Infection
Terminal complement inhibition can prevent membrane attack complex injury at the AChR positive neuromuscular junction. The benefit comes with a distinctive risk of rapidly fatal meningococcal infection that vaccination cannot eliminate.
- Eculizumab
- Ravulizumab
- Zilucoplan
- C5
- Meningococcal REMS
Current US MG labels for eculizumab, ravulizumab, and zilucoplan are phenotype specific.
Follow ACIP vaccination guidance, urgent prophylaxis when required, REMS, and safety-card instructions; younger children need a specialist plan.
Vaccination cannot eliminate meningococcal risk, so compatible illness needs immediate evaluation.
Match the antibody phenotype
Eculizumab is approved for AChR positive generalized MG from age 6, ravulizumab for AChR positive adults, and zilucoplan for AChR positive adults. These labels do not establish benefit for every seronegative or MuSK phenotype.
Block C5
These therapies prevent terminal complement activation and membrane attack complex formation. Eculizumab and ravulizumab are intravenous monoclonal antibodies, while zilucoplan is a once daily weight based subcutaneous peptide inhibitor.
Use the adult eculizumab MG regimen
Soliris for adult gMG begins with 900 mg IV weekly for four doses, followed one week later by 1,200 mg, then 1,200 mg every two weeks. Its PNH regimen is different. Eligible pediatric patients require the label’s weight-specific induction and maintenance table; do not automatically use adult doses.
Check eculizumab supplementation separately
For Soliris, acute rescue IVIG requires no supplemental dose. Scheduled IVIG does: the amount depends on the preceding Soliris dose, and timing depends on IVIG frequency. Plasma exchange or plasmapheresis requires 300 mg after a preceding 300 mg dose, or 600 mg after a preceding dose of at least 600 mg, within 60 minutes after each procedure. Fresh frozen plasma instead requires 300 mg 60 minutes before each infusion when the preceding dose was at least 300 mg. Reconcile the exact intervention with the label and treating team.
Prepare eculizumab for infusion
Dilute Soliris to 5 mg/mL: a 1,200 mg dose has a final volume of 240 mL. Infuse over 35 minutes in adults or one to four hours in pediatric patients; never give an IV push. Observe for at least one hour after completion for infusion reactions.
Separate ravulizumab loading from maintenance
For adult gMG, Ultomiris dosing starts at 40 kg. At 40 to below 60 kg, loading is 2,400 mg and maintenance is 3,000 mg; at 60 to below 100 kg, 2,700 mg and 3,300 mg; at 100 kg or more, 3,000 mg and 3,600 mg. Give the first maintenance infusion two weeks after loading, then every eight weeks. When switching from eculizumab, give the loading infusion when the next eculizumab dose was due.
Reconcile rescue treatment with ravulizumab
Plasma exchange, plasmapheresis and IVIG can reduce ravulizumab exposure. The label requires a supplemental dose within four hours after each exchange procedure or completion of an IVIG cycle. IVIG supplementation is 600 mg for the adult gMG weight bands; exchange supplementation depends on body weight and the most recent dose. Consult that table rather than copying an eculizumab protocol.
Choose the zilucoplan syringe by actual weight
Zilbrysq is injected subcutaneously once daily: below 56 kg, 16.6 mg; 56 to below 77 kg, 23 mg; and 77 kg or more, 32.4 mg. Select the prescribed single-dose syringe strength, not a fraction of another syringe or a universal mg/kg calculation.
Complete meningococcal prevention
Use current ACIP guidance for MenACWY and MenB vaccination, ideally at least two weeks before the first dose. If urgent treatment cannot wait, follow the label for antibacterial prophylaxis and vaccinate as soon as possible.
Maintain protection over time
For adults who remain on complement inhibition, MenACWY boosters are due every five years. High-risk MenB vaccination uses a three-dose primary series, then a booster one year after completion and every two to three years while risk persists. Reconcile prior products and doses; use the same MenB product throughout. Vaccination is an ongoing plan, not a one-time clearance.
Individualize pediatric prevention
Soliris has an MG indication from age six, but US high-risk MenB recommendations begin at age ten. Do not copy an adult schedule into a younger child. Coordinate age-appropriate vaccination and infection prevention with pediatric specialists. MenACWY booster timing also differs when the primary series is completed before age seven.
Consider prophylaxis beyond urgent initiation
The labels require antibacterial prophylaxis when urgent initiation precedes up-to-date vaccination. CDC also permits considering prophylaxis during complement therapy more broadly. Select the drug and duration with the treating team, accounting for MG medication cautions and local resistance. Neither antibiotics nor vaccination eliminates the need for immediate evaluation of compatible symptoms.
Teach residual risk
Vaccination reduces but does not eliminate meningococcal risk. Fever, severe headache, neck stiffness, photophobia, confusion, rash, myalgia, or rapidly progressive illness requires immediate evaluation. Product REMS and safety card requirements must be followed.
Protect the pancreas with zilucoplan
Obtain baseline lipase and amylase. Pancreatitis and pancreatic cysts have been reported, so new persistent abdominal pain, nausea, or vomiting requires evaluation and suspected pancreatitis requires treatment interruption while assessed.
Quick check
Checking for saved practice…
Lesson
Prevent Avoidable Worsening Across the Care Plan
Medication cautions in MG are clinically important, but most are not automatic universal contraindications. The right response is to identify the strength of association, necessity, safer alternatives, dose, route, and monitoring capacity.
- Medication review
- Magnesium
- Antibiotics
- Pregnancy
- Anesthesia
Telithromycin, fluoroquinolones, IV magnesium, and other exposures do not carry identical evidence.
Neurology, obstetrics, anesthesia, pharmacy, and surgery need one shared MG plan.
Rapidly worse swallowing, cough, head control, or breathing requires urgent care.
Use the caution list precisely
Telithromycin carries the strongest warning and should not be used. Fluoroquinolones have an FDA boxed warning for worsening MG. Aminoglycosides, macrolides, beta blockers, procainamide, botulinum toxin, D penicillamine, selected antipsychotics, neuromuscular blockers, and other agents require avoidance or careful benefit and risk review according to the situation.
Recognize additional medication signals
Hydroxychloroquine, chloroquine and statins may precipitate or worsen MG; assess indication and alternatives rather than stopping necessary treatment automatically. Modern iodinated contrast appears safer than older agents, but monitor for worsening. Botulinum toxin and D-penicillamine deserve avoidance, not routine inclusion among low-risk choices.
Escalate checkpoint-inhibitor weakness
New ptosis, swallowing difficulty or respiratory weakness during cancer immunotherapy requires urgent oncology and neurology assessment. Checkpoint-inhibitor-associated MG may coexist with myositis and myocarditis. Do not attribute this pattern to ordinary cancer-treatment fatigue or wait for severe oxygen desaturation.
Treat magnesium as route and dose dependent
Intravenous magnesium can significantly impair neuromuscular transmission and may be dangerous. Oral replacement still requires a reason, dose, kidney function review, and symptom monitoring rather than a blanket assumption that every trace exposure is forbidden.
Plan pregnancy before it begins
Oral pyridostigmine is usually first line for symptom control in pregnancy. IV cholinesterase inhibitors can provoke uterine contractions. Immunotherapy and targeted therapy require product specific reproductive review, while thymectomy is generally deferred until after pregnancy.
Plan delivery and neonatal observation
MG alone does not mandate cesarean delivery; hospital vaginal delivery is often appropriate when obstetric circumstances permit. Arrange neonatal observation because transferred maternal antibodies can cause transient weakness, poor feeding or respiratory difficulty even when maternal MG is controlled. Symptoms may emerge after birth rather than immediately.
Protect control after delivery
Postpartum exacerbation is possible. Coordinate medication, breastfeeding and follow-up plans before delivery, and avoid abrupt withdrawal of effective immunotherapy. Mycophenolate and methotrexate should be avoided in pregnancy; alternatives require individualized specialist review. A well-controlled mother does not eliminate the newborn’s monitoring needs.
Assess cardiovascular and local-anesthetic cautions
Calcium-channel blockers such as verapamil, diltiazem and nifedipine appear on specialist MG caution lists; use a patient-specific assessment of necessity, alternatives and weakness after initiation. Local or regional anesthesia is possible. Ester local anesthetics have a theoretical metabolism concern with cholinesterase inhibitors, and excessive systemic exposure to any local anesthetic can impair muscle function. The anesthesia team should select agent, dose and monitoring.
Coordinate anesthesia
MG changes sensitivity to nondepolarizing neuromuscular blockers and can alter response to other anesthetic drugs. The anesthesia team needs current respiratory and bulbar status, antibody phenotype, medicine timing, prior crisis history, and a postoperative ventilation plan.
Give an escalation script
Patients should seek urgent care for rapidly worse speech, swallowing, cough, head control, breathing, or generalized weakness. They should not stop essential therapy or start a new prescription, OTC product, supplement, or infusion without checking the MG plan.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 38 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Koneczny et al.: MuSK antibodies and AChR clustering (primary experimental study)
- MGFA: Overview of MG
- OrphanAnesthesia: Myasthenia gravis recommendations
- DailyMed: Neoral prescribing information
- International MG consensus guidance: 2016
- Genentech: CellCept prescribing information
- DailyMed: Prograf prescribing information
- DailyMed: Imuran prescribing information
- Genentech: Rituxan prescribing information
- CDC: Complement inhibitor meningococcal risk
- CDC: Meningococcal vaccine recommendations
- DailyMed: Soliris current label
- DailyMed: Ultomiris current label
- International Consensus Guidance for Management of Myasthenia Gravis, 2020 Update
- Guideline for the Management of Myasthenic Syndromes
- Myasthenia Gravis Foundation of America, Cautionary Drugs
- DailyMed: Imaavy current prescribing information
- DailyMed: Zilbrysq current label
- DailyMed: Rystiggo current prescribing information
- DailyMed: Mestinon oral formulations
- DailyMed: Regonol injection
- DailyMed: Pyridostigmine soman pretreatment product
- MGFA: Emergency management for first responders
- ABN 2025 myasthenia gravis management guideline
- DailyMed: Vyvgart current prescribing information
- DailyMed: Vyvgart Hytrulo current prescribing information